[1] Yang G, Yan H, Tang Y, et al. Advancements in understanding mechanisms of hepatocellular carcinoma radiosensitivity: a comprehensive review[J]. Chin J Cancer Res 2023, 35(3): 266-282.
[2] Vogel A, Meyer T ,Sapisochin G , et al. Hepatocellular carcinoma[J]. Lancet (London, England), 2022, 400(10360): 1345-1362.
[3] Papaconstantinou D,Tsilimigras D I, Pawlik T M. Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment[J]. Journal of Hepatocellular Carcinoma, 2022, 9:947-957.
[4] Li X Y, Shen Y ,Zhang L , et al. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing[J]. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022, 1877(3): 188720.
[5] Shi Q,Chen Y, Li Y, et al. Cross-tissue multicellular coordination and its rewiring in cancer[J]. Nature, 2025, 643(8071): 529-538.
[6] Liu F, X Li,Zhang Y, et al. Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma[J]. Journal of Experimental & Clinical Cancer Research, 2025, 44(1): 227.
[7] Li J,Wang D ,Tang F , et al. Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers[J]. National Science Review, 2024, 11(9): nwae231.
[8] Fitzsimons E, Qian D, Enica A , et al. A pan-cancer single-cell RNA-seq atlas of intratumoral B cells[J]. Cancer Cell, 2024, 42(10): 1784-1797.e4.
[9] Jia G,He P ,Dai T , et al. Spatial immune scoring system predicts hepatocellular carcinoma recurrence[J]. Nature, 2025, 640(8060): 1031-1041.
[10] Chen S,Huang C, Liao G , et al. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences[J]. Gut, 2023, 72(6): 1196-1210.
[11] Peng D,Fu M ,Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Molecular Cancer, 2022, 21(1): 104.
[12] Li M,Wang L ,Cong L , et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma[J]. Hepatology (Baltimore, Md.), 2024, 79(3): 560-574.
[13] Chan Y T,Zhang C ,Wu J , et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma[J]. Mol Cancer, 2024, 23(1): 189.
[14] Yang M, Song X ,Zhang F , et al. Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse[J]. Hepatology (Baltimore, Md.), 2025, 81(5): 1452-1467.
[15] Chang J Q,Guo Y ,Yuan W J , et al. HLA-DR+ tumor cells show an association with a distinct immune microenvironment and CD8+ T-cell exhaustion in HBV-associated hepatocellular carcinoma[J]. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 2025, e02979.
[16] Gao Y, Zhang Z ,Huang X , et al. HBV-associated hepatocellular carcinomas inhibit antitumor CD8+ T cell via the long noncoding RNA HDAC2-AS2[J].Nature Communications, 2025, 16(1): 2055.
[17] Liu Z, Naz W ,Yousaf T, et al. Viral-track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma[J]. Communications Biology, 2025, 8(1): 1030.
[18] Chen W,Jiang J ,Gong L , et al. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis[J]. Journal of experimental & clinical cancer research: CR, 2021, 40(1): 1.
[19] Zhong Y, Stalin A ,Dai Y , et al. Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma[J]. Scientific Reports, 2025, 15(1): 26038.
[20] Sugiyama M,Nishida N, Khor S S, et al. Human leukocyte antigen genotypes affect Hepatitis B virus mutations associated with hepatocellular carcinoma[J]. Hepatol Res, 2025. |
